1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Estradiol Vaginal Ring

Trade Name: ESTRING; ELLESTE; OESTRING

Chemical Family: Steroid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as hormone replacement therapy

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification: Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Note: No data available

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
</table>

PZ00639
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol</td>
<td>50-28-2</td>
<td>200-023-8</td>
<td>Carc.1A (H350)</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.1A (H360FD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aquatic Acute 1 (H400)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aquatic Chronic 1 (H410)</td>
<td></td>
</tr>
<tr>
<td>Barium sulfate USP</td>
<td>7727-43-7</td>
<td>231-784-4</td>
<td>Acute Tox. 4 (H302)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>444-260-7</td>
<td>Acute Tox. 4 (H332)</td>
<td></td>
</tr>
</tbody>
</table>

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.

Skin Contact: Wash hands and arms thoroughly after handling this material. Obtain medical assistance if skin effects occur.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Due to the nature of this material first aid is not normally required. If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: May include oxides of carbon, silicone.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Estradiol

Pfizer OEL TWA-8 Hr: 0.2 µg/m³, Skin

Barium sulfate USP

ACGIH Threshold Limit Value (TWA) 10 mg/m³
ACGIH OELs - Notice of Intended Changes Listed
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Germany (DFG) - MAK 4 mg/m³
1.5 mg/m³
Ireland OEL - TWAs 2 mg/m³
OSHA - Final PELS - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Slovakia OEL - TWA 1.5 mg/m³
Spain OEL - TWA 10 mg/m³

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:
Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:
Wear safety glasses or goggles if eye contact is possible.

Skin:
Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:
If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Solid</th>
<th>Color:</th>
<th>Whitish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available.</td>
<td>Odor Threshold:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Estradiol
No data available

Polymer mixture
No data available

Barium sulfate USP
No data available

Decomposition Temperature (°C):
No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
10. STABILITY AND REACTIVITY

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient(s).

Short Term: May be absorbed through the skin and cause systemic effects.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).

Known Clinical Effects: Clinical use of this drug has caused headache, menstrual irregularities, changes in cervical erosion and secretion, breast enlargement, breast pain, nausea, vomiting, abdominal cramping, weight changes, fluid retention, loss of hair, mental depression. Other less common effects include breast cancer, uterine cancer, stroke, blood clots, mental confusion, and gallbladder disease.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Estradiol
90 Day(s) Rat Oral 0.003 mg/kg/day NOAEL Blood, Female reproductive system, Male reproductive system, Endocrine system, Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Estradiol
Reproductive & Fertility-Females Rat Oral 0.003 mg/kg/day LOAEL Reproductive toxicity
Embryo / Fetal Development Rat Intramuscular 30 mg/kg/day LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Estradiol
Sister Chromatid Exchange Human Lymphocytes Positive
Micronucleus Human Positive
Chromosome Aberration Human Negative
In Vivo Direct DNA Damage Hamster Positive
In Vivo Micronucleus Rodent Bone Marrow Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Estradiol
2 Year(s) Female Mouse Oral 0.1 mg/kg LOEL Tumors, Mammary gland, Female reproductive system

Carcinogen Status: See below
11. TOXICOLOGICAL INFORMATION

IARC: Group 1 (Carcinogenic to Humans)
NTP: Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Estradiol

- *Daphnia magna* (Water Flea) N/A LC50 48 Hours 0.0039 mg/L
- *Oncorhynchus mykiss* (Rainbow Trout) N/A LC50 96 Hours > 0.05 mg/L
- *Desmodesmus subcapitata* (Green Alga) N/A NOEC 72 Hours 2.48 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Estradiol

- *Pimephales promelas* (Fathead Minnow) N/A 92 Day(s) NOEC 0.000008 mg/L Reproduction

Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Estradiol

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed_carcinogen initial date 1/1/88
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List: 200-023-8

Polymer mixture

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
EU EINECS/ELINCS List: Not Listed

Barium sulfate USP

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: 231-784-4
444-260-7

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled
Carcinogenicity-Cat.1A; H350 - May cause cancer
Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 7 - Handling and Storage. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 16-May-2016

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

PZ00639
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet